Breast Cancer
Conditions
Brief summary
The purpose of this study is to help better understand the uptake and impact of genetic testing for women diagnosed with breast cancer who do not meet National Comprehensive Cancer Network (NCCN) criteria for genetic testing. By doing so, the research team will gain a better understanding of the clinical implications for offering genetic testing for all patients recently diagnosed with breast cancer versus only offering genetic testing to those meeting NCCN criteria. By offering genetic counseling and genetic testing to all women recently diagnosed with breast cancer, there will be a shortage of genetic counselors. This study will also assess the feasibility of using artificial intelligence to assist in the genetic counseling process.
Detailed description
This is a randomized trial comparing the effectiveness of pre-test genetic counseling using an artificial intelligence program and traditional in-person genetic counseling in women newly diagnosed with breast cancer who do not currently meet National Comprehensive Cancer Network (NCCN) criteria for genetic testing. The primary objectives of this study are: 1. To determine up-take of testing for those who do not meet NCCN guidelines for genetic testing 2. To assess overall patient satisfaction and comprehension in both groups The secondary objectives of this study are: 1. To assess mutation rate in the overall cohort 2. Identify reasons for not pursuing genetic testing 3. Identify any specific areas of improvement in satisfaction and comprehension 4. Assess the impact of genetic testing on Time to Treatment in this cohort 5. Develop workflow for offering genetic testing, providing pre-test genetic counseling, ordering testing, and delivering results
Interventions
GENETICAutomated program (ChatBot)
Pre-test counseling and information through a pre-test automated genetic counseling program (ChatBot)
GENETICGenetics counselor
Traditional in-person genetic counseling
OTHERBCGCKQ Survey
Survey assessing Breast Cancer Genetic Counseling Knowledge Questionnaire (BCGCKQ)
OTHERSatisfaction Survey
Survey assessing satisfaction with Decision-Genetic Testing
DEVICEGenetic testing
Genetic testing for all participants will assess for a mutation in 47 genes commonly associated with hereditary cancer syndromes (Invitae's Common Hereditary Cancer Panel) for those who choose to complete testing.
Sponsors
Case Comprehensive Cancer Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects diagnosed with Stage 0-3 breast cancer. * Patients who do not satisfy current NCCN criteria for referral to a genetics counselor and genetics testing. * Must have the ability to understand and the willingness to sign a written informed consent document as well as complete the study questionnaires.
Exclusion criteria
\- N/A
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percent of participants who took up genetic testing after not meeting NCCN guidelines for genetic testing | 2 years | Up-take of testing for those who do not meet NCCN guidelines for genetic testing |
| Mean overall patient satisfaction with decision about genetic testing: survey | 2 years | Mean overall patient satisfaction with decision about genetic testing as assessed by survey. The survey is a previously validated six-question Likert scale based survey. The scale ranges from 6 to 30, with higher scores indicating more satisfaction. Satisfaction will be compared between groups with t-test or Wilcoxon rank sum test. Published data suggest that standard deviation on the satisfaction survey is 3. A 2 point difference in average satisfaction score between groups is considered to be relevant |
| Overall comprehension as assessed by BCGCKQ | 3 years | Comprehension as assessed by previously validated survey consisting of 27 questions, which are a blend of True or False and multiple choice questions. The scale ranges from to , with higher scores indicating more comprehension. Comprehension will be compared between groups with t-test or Wilcoxon rank sum test. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of overall cohort with mutation | 2 years | Mutation rate as described by percentage of overall cohort with mutation. Groups will be compared with Chi-square test or Fisher's exact test |
| Number of patients who decline genetic testing | 2 years | Number of patients who decline genetic testing. Groups will be compared with Chi-square test or Fisher's exact test |
| Frequencies of most common reasons for not pursuing genetic testing | 2 years | Reasons for not pursuing genetic testing in those who declined will be collected as a descriptive measure and then analyzed as frequencies of the different responses, summarizing the most common answers |
| Time to treatment | 3 years | Time to treatment will be compared between patients who had genetic testing to those who did not using t-test or Wilcoxon rank sum test among all study patients. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORZahraa Al-Hilli, MD
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Outcome results
None listed